Effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.

Trial Identifier:	D1690C00047
Sponsor:	AstraZeneca
NCTID::	NCT03338855
Start Date:	March 2018
Primary Completion Date:	November 2019
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Translation
	Dutch Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Netherlands	Maastricht, Netherlands, 6229 ER

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.